CEACAM5 and inflammatory bowel disease: The deficiency of CEACAM5 in IBD patients inhibited CD8+ suppressor T cells activation, which led to the failure of suppressing CD4+ Th cell activation, thus resulting in pro-inflammatory factor release and inflammation progression.